Skip to content
Winnowleaf home

Condition

Immune Thrombocytopenia

Immune thrombocytopenia is a condition in which the immune system mistakenly attacks platelets, the cell fragments that help blood clot, so counts fall and bruising and bleeding become likelier. The strongest evidence is for romiplostim, a medicine, and trials found lasting platelet responses in 38% of adults without a spleen and 52% of children, versus 0% and 10% on placebo. Those results come from specific groups, so they may not apply to everyone.

Sources: PMID 27103127

Supplements studied
0
Medicines and peptides
1
Graded outcomes
4
No supplement studies yetWe haven’t found supplement studies for Immune Thrombocytopenia. The medicines and peptides studied for it are listed below.

Prescription medicines and peptides studied, for context

These are not supplements. Most need a prescription, and some are research compounds with no approved use.

1 medicine or peptide

Romiplostim (Nplate)

Romiplostim (Nplate): outcomes studied for Immune Thrombocytopenia
GradeOutcomeEffectSizeStudiesPeopleStudies list
Durable Platelet Response

Phase 3: 38% durable response (≥50,000/μL for ≥6 of last 8 weeks) in splenectomized vs 0% placebo (P=0.0013). 52% durable response in pediatric patients vs 10% placebo (P=0.002, OR 9.1).

Improves (the measure goes up)Large effect13 studies

Studies that measured durable platelet response

and 10 more on the Romiplostim (Nplate) page

Overall Platelet Response

Phase 3: 88% non-splenectomized and 79% splenectomized achieved platelet response vs 14% and 0% placebo (P<0.0001). Mean 13.8 weeks with platelets ≥50,000/μL vs 0.8 weeks placebo.

Improves (the measure goes up)Large effect13 studies

Studies that measured overall platelet response

and 10 more on the Romiplostim (Nplate) page

Long-term Efficacy

5-year extension: 95% achieved platelet response at least once. Platelet response maintained at median 92% of visits. Stable doses (mean 5-8 μg/kg) with platelets 50-200,000/μL throughout.

Improves (the measure goes up)Large effect13 studies

Studies that measured long-term efficacy

and 10 more on the Romiplostim (Nplate) page

Bleeding Reduction

Reduced bleeding events vs placebo. Lower rescue medication use. Decreased need for concurrent ITP therapies. Safe long-term with no increased thrombosis or malignancy risk.

Improves (the measure goes down)Large effect13 studies

Studies that measured bleeding reduction

and 10 more on the Romiplostim (Nplate) page

Key findings

  • Durable Platelet ResponseRomiplostim (Nplate)Improves (the measure goes up)
  • Overall Platelet ResponseRomiplostim (Nplate)Improves (the measure goes up)
  • Long-term EfficacyRomiplostim (Nplate)Improves (the measure goes up)

Safety notes in the studies

  • Safe long-term with no increased thrombosis or malignancy risk.

Studies cited

16 studies from PubMed

  1. Romiplostim with ciclosporin A in patients with aplastic anaemia naïve to immunosuppressive therapy: A phase 2/3 study.British journal of haematology, 2025 · PMID 40639944
  2. Predictive factors of romiplostim response in patients with refractory aplastic anemia: data from two clinical trials.Annals of hematology, 2025 · PMID 40593138
  3. A Review on Romiplostim Mechanism of Action and the Expressive Approach in E. coli.Recent patents on biotechnology, 2024 · PMID 38282441
  4. Romiplostim in primary immune thrombocytopenia that is persistent or chronic: phase III multicenter, randomized, placebo-controlled clinical trial in ChinaHaematologica, 2024 · PMID 37601010
  5. Efficacy and quality of life of Romiplostim in adults and children with immune thrombocytopenia: A review.Medicine, 2022 · PMID 36550870
  6. Assessment of romiplostim immunogenicity in pediatric patients in clinical trials and in a global postmarketing registry.Blood advances, 2021 · PMID 34638135
  7. A Review of Romiplostim Mechanism of Action and Clinical Applicability.Drug design, development and therapy, 2021 · PMID 34079225
  8. Assessment of romiplostim immunogenicity in adult patients in clinical trials and in a global postmarketing registry.British journal of haematology, 2020 · PMID 32311075
  9. Romiplostim in patients undergoing hematopoietic stem cell transplantation: results of a phase 1/2 multicenter trial.Blood, 2020 · PMID 31805185
  10. Romiplostim Treatment of Chemotherapy-Induced ThrombocytopeniaJ Clin Oncol, 2019 · PMID 31545663
  11. Efficacy of romiplostim in the treatment of ITP in children: a meta-analysis.European review for medical and pharmacological sciences, 2018 · PMID 30280805
  12. Romiplostim in children with immune thrombocytopenia: a phase 3, randomised, double-blind, placebo-controlled studyLancet, 2016 · PMID 27103127
  13. Long-term treatment with romiplostim in patients with chronic immune thrombocytopenia: safety and efficacyBr J Haematol, 2013 · PMID 23432528
  14. Romiplostim for the treatment of chronic immune thrombocytopenia in adult Japanese patients: a double-blind, randomized Phase III clinical trialInt J Hematol, 2011 · PMID 21706145
  15. Evaluation of bleeding and thrombotic events during long-term use of romiplostim in patients with chronic immune thrombocytopenia (ITP)J Thromb Haemost, 2010 · PMID 20230419
  16. Efficacy of romiplostim in patients with chronic immune thrombocytopenic purpura: a double-blind randomised controlled trialLancet, 2008 · PMID 18242413